Prior Authorization Reform for Autoimmune and Blood Disorders Act
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The bill forces group health plans and health insurers to cover any drug used to treat autoimmune diseases, hemophilia, or Von Willebrand disease, no matter how the drug is provided. It also bars them from requiring more than one prior‑authorization request for the same drug within a 12‑month period, except for short‑term treatments, certain controlled substances, or drugs that have a federal risk‑evaluation requirement. The goal is to speed patient access and cut administrative burdens.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 9192 changes status, plus AI-powered summaries and stage predictions.
Sign up free